drugset / Trial / NCT02465957
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).
Timeline
- Start
- 2015-09-24
- Primary completion
- 2018-03-19
- Completion
- 2018-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Subject | aNK | Cell therapy | 2e+09 unknown | Intravenous |